Key points are not available for this paper at this time.
Extract For patients with newly diagnosed idiopathic pulmonary arterial hypertension (IPAH) at high risk of death, current guidelines recommend initial triple combination therapy consisting of an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and a parenteral prostacyclin analogue 1.
Park et al. (Thu,) studied this question.